Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18925875
García-Martínez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416, 375-85 18925875
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T346-p - NDRG1 (human)
Modsite: GtRsRsHtsEGtRsR SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): T346‑p, NDRG1 iso2 (human): T280‑p, NDRG1 iso3 (human): T265‑p, NDRG1 (mouse): T346‑p, NDRG1 (rat): T346‑p, NDRG1 (cow): T346‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SGK1 (human) increase
PI-103 SGK1 (human) inhibit treatment-induced increase
rapamycin SGK1 (human) no effect upon treatment-induced increase

T356-p - NDRG1 (human)
Modsite: GtRsRsHtsEGtRsR SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): T356‑p, NDRG1 iso2 (human): T290‑p, NDRG1 iso3 (human): T275‑p, NDRG1 (mouse): T356‑p, NDRG1 (rat): T356‑p, NDRG1 (cow):
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SGK1 (human) increase
PI-103 SGK1 (human) inhibit treatment-induced increase
rapamycin SGK1 (human) no effect upon treatment-induced increase

T366-p - NDRG1 (human)
Modsite: GtRsRsHtsEGAHLD SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): T366‑p, NDRG1 iso2 (human): T300‑p, NDRG1 iso3 (human): T285‑p, NDRG1 (mouse): T366‑p, NDRG1 (rat): T366‑p, NDRG1 (cow): T356‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SGK1 (human) increase
PI-103 SGK1 (human) inhibit treatment-induced increase
rapamycin SGK1 (human) no effect upon treatment-induced increase

S422-p - SGK1 (human)
Modsite: AEAFLGFsYAPPTDS SwissProt Entrez-Gene
Orthologous residues
SGK1 (human): S422‑p, SGK1 iso2 (human): S517‑p, SGK1 iso3 (human): S436‑p, SGK1 (mouse): S422‑p, SGK1 (rat): S421‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical), MCF-7 (breast cell), MEF (fibroblast), MEF (fibroblast) [mTOR (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE mTOR (human)
Comments:  mTOR complex 2
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SGK1 (human) increase
PI-103 SGK1 (human) inhibit treatment-induced increase
rapamycin SGK1 (human) no effect upon treatment-induced increase

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical), MCF-7 (breast cell), MEF (fibroblast) [mTOR (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse

T346-p - NDRG1 (mouse)
Modsite: GtRsRsHtsEGPRsR SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): T346‑p, NDRG1 iso2 (human): T280‑p, NDRG1 iso3 (human): T265‑p, NDRG1 (mouse): T346‑p, NDRG1 (rat): T346‑p, NDRG1 (cow): T346‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RICTOR (mouse) increase
Sin1 (mouse) increase
LST8 (mouse) increase

T356-p - NDRG1 (mouse)
Modsite: GPRsRsHtsEGsRsR SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): T356‑p, NDRG1 iso2 (human): T290‑p, NDRG1 iso3 (human): T275‑p, NDRG1 (mouse): T356‑p, NDRG1 (rat): T356‑p, NDRG1 (cow):
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RICTOR (mouse) increase
Sin1 (mouse) increase
LST8 (mouse) increase

T366-p - NDRG1 (mouse)
Modsite: GsRsRsHtsEDARLN SwissProt Entrez-Gene
Orthologous residues
NDRG1 (human): T366‑p, NDRG1 iso2 (human): T300‑p, NDRG1 iso3 (human): T285‑p, NDRG1 (mouse): T366‑p, NDRG1 (rat): T366‑p, NDRG1 (cow): T356‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
RICTOR (mouse) increase
Sin1 (mouse) increase
LST8 (mouse) increase

T412-p - p70S6K (mouse)
Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical), MCF-7 (breast cell), MEF (fibroblast) [mTOR (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE mTOR (human)
Comments:  mTOR complex 1
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SGK1 (human) no change compared to control
PI-103 decrease
rapamycin decrease